News | Robotic Systems | May 13, 2016

New Study Reveals Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Cases

corpath, corindus, cath lab robot, CORA-PCI

May 13, 2016 — A first-of-its kind study using robotic technology to remotely control coronary guidewires and stents reported on the feasibility of performing percutaneous coronary intervention (PCI) on patients with complex coronary lesions. Similar clinical outcomes compared to the PCI procedure performed manually were reported. Results of the 18-month complex robotically assisted percutaneous coronary intervention (CORA-PCI) trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions. 

The technology of performing robotically assisted PCI is relatively new and was recently approved by the FDA. Previous studies were performed largely on patients with simple coronary lesions. “For the first time, we’ve shown nearly identical outcomes with a group of very complex patients,” said Ehtisham Mahmud, M.D., FACC, FSCAI, the study’s lead author and division chief, cardiovascular medicine and director, interventional cardiology and cardiac cath lab at the University of California, San Diego School of Medicine. He noted that approximately 80 percent of lesions treated in the CORA-PCI trial were complex, which is more reflective of contemporary interventional cardiology practice.

Consecutive robotic and manual procedures were performed by a single operator and a total of 334 PCI procedures were analyzed (108 robotic, 157 lesions; 226 manual, 336 lesions) in 315 patients (age 67.7 ± 11.8). The majority of patients (78 percent) were male. Clinical success was similar between the groups (99.1 percent for robotic PCI vs. 99.6 percent for manual PCI, p=0.64).

In the robotically assisted PCI group, over 90 percent of the procedures were performed entirely robotically or with minimal manual assistance. Procedure time was longer (robotic PCI 44:30 ± 26:04 min vs. manual PCI 36:34 ± 23:03 min, p=0.005) and remained significant after accounting for Syntax score, primary lesion length, and complexity (p=0.026); however, the longer procedure time was limited to the low complexity lesions. Propensity matched analysis (n=94 each group) confirmed the longer procedure time in the R-PCI group with comparable clinical success (98.9 percent vs. 100 percent, p=1). No increase in resource utilization or patient radiation exposure was reported with robotic PCI.

Furthermore, Mahmud said the data presented show that using robotic technology to perform PCI is a viable alternative to manual PCI with the potential benefits of reducing radiation exposure and orthopedic injuries to the interventional cardiologist.

Mahmud reports the following disclosures: Corindus, consulting and clinical trial support. No support received for this study.

For more information: www. SCAI.org/SCAI2016 


Related Content

News | Robotic Systems

March 18, 2024 — SS Innovations International, Inc., a developer of innovative surgical robotic technologies dedicated ...

Home March 18, 2024
Home
News | Robotic Systems

March 12, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home March 12, 2024
Home
News | Robotic Systems

January 8, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention ...

Home January 08, 2024
Home
News | Robotic Systems

December 27, 2023 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, and ...

Home December 27, 2023
Home
News | Robotic Systems

November 7, 2023 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home November 07, 2023
Home
News | Robotic Systems

July 19, 2023 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home July 19, 2023
Home
News | Robotic Systems

May 24, 2023 — Stereotaxis announced a global collaboration with Abbott to integrate Abbott’s EnSite X EP System with ...

Home May 24, 2023
Home
News | Robotic Systems

May 17, 2023 — Robocath, a company that designs, develops and commercializes smart robotic solutions for the treatment ...

Home May 17, 2023
Home
News | Robotic Systems

March 30, 2023 — Stereotaxis, a global leader in innovative robotic technologies for the treatment of cardiac ...

Home March 30, 2023
Home
News | Robotic Systems

October 20, 2022 — A team of Case Western Reserve University scientists has received a four-year, $3.7 million National ...

Home October 20, 2022
Home
Subscribe Now